FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 524615166 US Express Mail Label Number

20. Other items or information: Unexecuted Declaration

15 April 2005 Date of Deposit

(REV 10-96)			PC/4-32727A								
TRANSMITTAL LE	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)										
DESIGNATED/E CONCERNING A	10/531515										
INTERNATIONAL APPLICATION	PRIORITY DATE CLAIMED										
PCT/EP03/11554	CT/EP03/11554 17 October 2003 (17.10.03)										
TITLE OF INVENTION MODULATION OF S6 KINASE ACTIVITY FOR THE TREATMENT OF OBESITY											
APPLICANT(S) FOR DO/EO/US FRIGERIO ET AL.											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority 											
date. 5. 🖂 A copy of the International Application as filed (35 U.S.C. 371(c)(2))											
 a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US). 											
	☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)). ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).										
a. are transmitted he	a. are transmitted herewith (required only if not transmitted by the International Bureau).										
c. have been transm	 b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. 										
	d. 🛛 have not been made and will not be made.										
9. An executed Declaration a	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.										
Items 11. to 16. below concern document(s) or information included.											
11. An Information Disclosure	Statement under 3	37 CFR 1.97 and 1.98.	,								
12. An assignment document	☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
	 A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 										
14. An Application Data Shee	t under 37 CFR 1.7	6.									
15. A substitute specification.											
16. A change of power of attorney and/or address letter.											
17. A computer-readable form	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.										
18. A second copy of the pub	8. A second copy of the published International Application under 35 U.S.C. 154(d)(4).										
19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).											

JC12 Rec'd PCT/PTC 1 5 APR 2005

U.S. APPLICATIONNO	(inknowings	° 167 958 161					PC/4-3272	DOCKET NUMBER			
The following fe	es are su	ubmitted:							CULATIO	NS PTO USE	
								ONLY			
21. 🛛 Basic national fee											
22. Examination Fee											
☐ If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$											
. and a	an Clantis	s sausiy pio	VISIONS OF FO	Article 30(1)-(4)		•••	Ψ				
. ☐ All other situations											
23. Search fee											
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$400											
All other situations											
			TOTAL OF	= 21, 22 AND 23 =			'	\$	900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer											
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra	sheets		ach additional 50 or fraction dup to a whole number)	n	R	ATE				
47 - 100 =	0	/50 =	thoroor trous	0		X \$	250	\$			
	00 ((
Surcharge of \$1 months from the								\$:	
CLAIMS			ER FILED	NUMBER EXTRA		RAT	Έ				
Total claims		26	- 20 =	6	X		50	\$	300		
Independent cla		T CLAIM(S)	- 3 =	8	X		200 360	\$	1,600		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360 TOTAL OF ABOVE CALCULATIONS =								\$	2,800		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be											
filed (Note 37 CFR 1.9, 1.27, 1.28).							\$	2 200			
SUBTOTAL =						1 3	2,800				
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$		-		
TOTAL NATIONAL FEE =							\$	2,800	• , ,		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +											
by an appropriat	e cover	sheet (37 C	FR 3.28, 3.31		EEE	S ENCI	OSED =	\$	2,800		
				IOIAL	1 66	-3 LINUI	_ 		Amount to	\$	
									refunded	Ð	
									charged	\$	
a. A chec	k in the a	amount of \$		to cover the above fee	es is	enclosed.					
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$2,800 to cover the above fees. A duplicate copy of this form is enclosed.											
•				to charge any additional fe	es w	hich mav	be required.	or cre	dit anv ove	erpayment to	
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
or (b)) must be	Tiled an	a granted t	o restore the	application to pending s	statu	s. •					
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
John T. Prince											
Novartis					rgey ·	for Applica	ints				
Corporate Intellectual Property Reg. No. 43,019 One Health Plaza, Building 104 (617) 871-3346											
East Hanover, NJ 07936-1080											
JP:rpg Date: April 15, 2	2005										